Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ORG-129 in Healthy Volunteers
NCT04933565Phase 1Completed
- Sponsor
- Agomab Therapeutics
- Start
- Jun 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Crohn's disease comparing Ontunisertib with Placebo (2 arms). Primary endpoints: Assessment of safety and tolerability of Single Ascending Dose of ORG-129 and Assessment of safety and tolerability of Multiple Ascending Dose of ORG-129. Started Jun 2021; status: completed.
02
Drugs
ontunisertib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT04933565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04933565.